Table 1.
Characteristics of study patients
| Baseline characteristics | Group R (n=16) | Group C (n=34) | Group B (n=65) |
|---|---|---|---|
| Duration of hypertension (years) | 5.72±1.74 | 5.81±1.85 | 5.95±2.02 |
| Age (years) | 63.8±8.1 | 66.7±7.8 | 67.6±8.5 |
| Sex, male/female | 8/8 | 13/21 | 39/21 |
| Laboratory intervals (days) | 419.8±215.8 | 471.6±274.4 | 356.2±212.9 |
| CAVI intervals (days) | 426.0±243.2 | 503.3±278.3 | 362.5±224.0* |
| Incidence: n (%) | |||
| Obesity | 7 (43.8) | 15 (44.1) | 26 (40.0) |
| Hyperlipidemia | 9 (56.3) | 18 (53.0) | 28 (43.1) |
| Diabetes mellitus | 3 (18.8) | 4 (11.8) | 10 (15.4) |
| Other BP-lowering drugs: n (%) | |||
| α-Blocker | 1 (6.3) | 1 (2.9) | 5 (7.7) |
| β-Blocker | 0 (0) | 3 (8.8) | 8 (12.3) |
| HMG-CoA reductase inhibitor, n (%) | 7 (43.8) | 14 (41.2) | 16 (24.6) |
| Glucose-lowering drugs, n (%) | 2 (12.5) | 2 (5.9) | 8 (12.3) |
Notes: Continuous data are expressed as the mean ± standard deviation. P-values were determined using one-way analysis of variance and Tukey–Kramer tests.
*
P<0.05 versus group C.
Abbreviations: CAVI, cardio-ankle vascular index; BP, blood pressure; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A.